Your new post is loading...
Targeting pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) has been an effective therapeutic approach in patients with a variety of autoimmune diseases, including psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. New targets along the interleukin-17 (IL-17)–TH17 (T helper cell 17) pathway,
Via Krishan Maggon
Targeting the IL-17–TH17 pathwayHilary S. Bartlett& Ryan P. MillionAffiliationsCorresponding authorsNature Reviews Drug Discovery 14, 11–12 (2015) doi:10.1038/nrd4518Published online 31 December 2014